Accessibility Menu
Dr. Reddy's Laboratories logo

Dr. Reddy's Laboratories(NYSE) RDY

Market Cap$9.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2001)+1,299%
5 Year-8%
1 Year-15%
1 Month-1%
Premium Feature
Moneyball Superscore
63/100
$11.84
-1.13%
-0.14Today
Dr. Reddy's Laboratories last closing stock price
MetricPriceDate
Last closeUSD 11.972026-09-04
Dr. Reddy's Laboratories stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.72%USD 12.182026-08-28
1 month-1.4%USD 12.142026-08-05
3 month-8.95%USD 13.152026-06-05
Year to date-14.14%USD 13.942025-12-31
1 year-14.8%USD 14.052025-09-04
3 year-8.81%USD 13.132023-09-05
5 year-7.74%USD 12.972021-09-03
Since inception+1,299.18%USD 0.862001-04-11

Dr. Reddy's Laboratories Financials at a Glance

Market Cap

$9.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

₹332.83B

Net Income (TTM)

₹33.17B

EPS (TTM)

$0.45

P/E Ratio

26.90

Dividend

$0.08

Beta (Volatility)

0.41 (Low)

Price

$11.84

Volume

996,122.311

Open

$11.78

Previous Close

$11.97

Daily Range

$11.69 - $11.87

52-Week Range

$11.36 - $15.67

Estimated Earnings Date

Oct 23, 2026

RDY News

A hand writing the words EMERGING MARKETS.

What Is an Emerging Market Economy?

Anders BylundSep 14, 2025
GettyImages-1132119369

2 Top Global Value Stocks to Buy Now

Zhiyuan SunJul 8, 2021
pharmaceutical worker wearing protective gear holds pills in hand

Why Is No One Talking About Dr. Reddy's Stock?

James HalleyMay 11, 2021
GettyImages-1141354730

Bristol-Myers Squibb Cuts Deal, Delaying Threat to Top-Selling Revlimid

Todd CampbellSep 17, 2020
GettyImages-185955499

Is Dr. Reddy's Laboratories a Buy?

Zhiyuan SunMay 10, 2020
093 legal settlement

Will a $48 Billion Global Settlement End U.S. Opioid Crisis Lawsuits?

Maxx ChatskoOct 23, 2019
GettyImages-493071639

Dr. Reddy's Laboratories Ltd (ADR) Is Tanking Today -- Here's Why

Brian FeroldiJul 26, 2016
15824975276_03f64d355f_z

3 Value Stocks Near 52-Week Lows Worth Buying

Sean WilliamsJan 5, 2016
Page 1

RDY: Motley Fool Moneyball Superscore

63

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Dr. Reddy's Laboratories

Dr. Reddy's Laboratories Limited is a global pharmaceutical company based in Hyderabad, India, specializing in the development and manufacturing of a wide range of pharmaceutical products. The company operates through various segments, including Global Generics, Pharmaceutical Services and Active Ingredients, Proprietary Products, and Others, addressing diverse therapeutic areas.

Products and Services
  • Generics and branded pharmaceuticals across multiple therapeutic areas
  • Active pharmaceutical ingredients (APIs) and contract research services
  • Innovative proprietary products targeting oncology and inflammatory conditions
Growth Outlook
  • Recent quarterly revenue reached INR 81.18 billion, indicating strong demand
  • Net income for Q1 2026 was INR 4.44 billion, showcasing profitability
  • Strategic partnerships, like with Curis, enhance product pipeline and market reach
Financial Highlights
  • Trailing twelve months (TTM) revenue of INR 309.5 billion reflects consistent growth
  • Operating profit margin of 10.64% indicates effective cost management
  • Current ratio of 1.90 suggests strong liquidity position
Dr. Reddy's Laboratories Limited has established itself as a key player in the pharmaceutical industry, with a diverse portfolio that caters to various health needs. The company's focus on generics and proprietary products, combined with its commitment to research and development, positions it well for future growth. Recent financial performance highlights, including a significant quarterly revenue and net income, underscore the company's operational efficiency and market demand. The strategic partnerships further enhance its growth potential, making it an attractive option for investors interested in the healthcare sector.
AI Generated • Aug 23, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

27,811

CEO

Erez Israeli, MBA

Website

www.drreddys.com

Headquarters

Hyderabad, TS 500034, IN

RDY Financials

Key Financial Metrics (TTM)

Gross Margin

50.18%

Operating Margin

10.64%

Net Income Margin

10.00%

Return on Equity

8.88%

Return on Capital

10.97%

Return on Assets

5.75%

Earnings Yield

3.72%

Dividend Yield

0.70%

Payout Ratio

20.11%

Stock Overview

Market Cap

$9.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

832.95M

Volume

996.12K

Avg. Volume

2.70M

Financials (TTM)

Gross Profit

₹166.92B

Operating Income

₹35.20B

EBITDA

₹55.60B

Operating Cash Flow

₹40.99B

Capital Expenditure

-₹25.85B

Free Cash Flow

₹15.15B

Cash & ST Invst.

₹81.43B

Total Debt

₹71.95B

Dr. Reddy's Laboratories Performance Analysis

Dr. Reddy's Laboratories annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31INR 3,060,162,5016.3%
20242024-03-31INR 3,372,211,74410.2%
20252025-03-31INR 3,850,357,35514.2%
20262026-03-31INR 3,801,955,901-1.3%
Dr. Reddy's Laboratories sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-303.0%
Q32025-12-31-0.9%
Q42026-03-31-12.5%
Q12026-06-306.4%
Dr. Reddy's Laboratories annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31INR 0.6777.3%
20242024-03-31INR 0.8119.7%
20252025-03-31INR 0.80-0.7%
20262026-03-31INR 0.58-27.4%
Dr. Reddy's Laboratories sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-301.4%
Q32025-12-31-15.8%
Q42026-03-31-81.5%
Q12026-06-3099.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2027YOY CHG

Revenue

₹81.18B

-5.0%

Gross Profit

₹37.76B

-22.3%

Gross Margin

46.52%

N/A

Market Cap

$9.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$362.20K

N/A

Employees

27,527

N/A

Net Income

₹4.46B

-68.5%

EBITDA

₹2.97B

-87.9%

Quarterly Fundamentals

Name
Q1 2027YOY CHG

Total Cash

₹81.43B

+22.1%

Total Debt

₹71.95B

+47.9%

Accounts Receivable

₹124.42B

+7.8%

Inventory

₹80.47B

+6.4%

Long Term Debt

₹11.88B

+133.2%

Short Term Debt

₹60.07B

+37.9%

Return on Assets

5.75%

N/A

Return on Invested Capital

8.43%

N/A

Free Cash Flow

-₹4.63B

-203.3%

Operating Cash Flow

-₹927.00M

-106.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ENSGThe Ensign Group, Inc.
$171.03+0.14%
EHCEncompass Health Corporation
$120.38-1.16%
ELANElanco Animal Health Incorporated
$24.02-1.98%
BMRNBioMarin Pharmaceutical Inc.
$65.22-1.97%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$104.70+0.09%
NOKNokia
$10.76+0.07%
NVDANvidia
$225.82-0.02%
BNCCea Industries
$5.29+0.51%

Questions About RDY

What is the current price of Dr. Reddy's Laboratories?

Dr. Reddy's Laboratories is trading at $11.83 per share.

What is the 52-week range for Dr. Reddy's Laboratories?

Over the past 52 weeks, Dr. Reddy's Laboratories has traded between $11.36 and $15.67.

How much debt does Dr. Reddy's Laboratories have?

As of the most recent reporting period, Dr. Reddy's Laboratories reported total debt of ₹760.12M.

How much cash does Dr. Reddy's Laboratories have on hand?

Dr. Reddy's Laboratories reported ₹118.36M in cash and cash equivalents in its most recent financial results.

What is Dr. Reddy's Laboratories’s dividend yield?

Dr. Reddy's Laboratories currently has a dividend yield of 0.70%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services